2(R)-N-hydroxy-1-(4-(4-chlorophenoxy)benzenesulfonyl)-piperazine-2-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2(R)-N-hydroxy-1-(4-(4-chlorophenoxy)benzenesulfonyl)-piperazine-2-carboxamide
• 英文别名: 1-[4-(4-chlorophenoxy)phenyl]sulfonyl-N-hydroxypiperazine-2-carboxamide
• 化学式: C₁₇H₁₈ClN₃O₅S
• 分子量: 411.866
• InChiKey: YQCULNLACGYFJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2(R)-N-(t-butyldimethylsilyloxy)-4-(t-butoxycarbonyl)-1-(4-(4-chlorophenoxy)benzenesulfonyl)-piperazine-2-carboxamide 在 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2(R)-N-hydroxy-1-(4-(4-chlorophenoxy)benzenesulfonyl)-piperazine-2-carboxamide
  参考文献：
  名称：

  Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

  摘要：

  这项发明涉及以下式子的化合物： 其中：Z为O或S；V为二价基团，与C*和N一起形成具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且其中至少一个其他环原子为从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化合物。 该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式I的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。

  公开号：

  US06500948B1

文献信息

• Metalloproteinase inhibitors and intermediates useful for their
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06153757A1

  公开（公告）日：2000-11-28

  The invention relates to compounds of formula (1) ##STR1## wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  该发明涉及式（1）的化合物##STR1##其中：Z为O或S；V为与C*和N一起形成具有六个环原子的环的二价基团，其中除C*和N之外的每个环原子独立地未取代或被适当取代基取代，且所述其他环原子中至少有一个是从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基团；以及其药学上可接受的前药、盐和溶剂化合物。该发明还涉及这些化合物的药学上可接受的前药、盐和溶剂。该发明还涉及通过给予式（1）的化合物或其前药、盐或溶剂来抑制金属蛋白酶活性的方法。该发明还涉及包含这些化合物、前药、盐和溶剂的有效量的药物组合物。该发明还涉及用于制备这些化合物、前药、盐和溶剂的方法和中间体。
• Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20030130506A1

  公开（公告）日：2003-07-10

  The invention relates to compounds of the formula 1: 1 wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  本发明涉及式1:1的化合物，其中：Z为O或S；V是一个二价基团，与C*和N一起形成具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代基团取代，且其中至少一个其他环原子是从O、N和S中选择的杂原子，其余是碳原子；Ar是芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化物。本发明还涉及这些化合物的药学上可接受的前药、盐和溶剂化物。本发明还涉及通过给予式I或其前药、盐或溶剂化物来抑制金属蛋白酶活性的方法。本发明还涉及包含这些化合物、前药、盐和溶剂化物的有效量的制药组合物。本发明还涉及用于制备这些化合物、前药、盐和溶剂化物的有用方法和中间体。
• US5753653A
  申请人：——

  公开号：US5753653A

  公开（公告）日：1998-05-19
• US6153757A
  申请人：——

  公开号：US6153757A

  公开（公告）日：2000-11-28
• US6500948B1
  申请人：——

  公开号：US6500948B1

  公开（公告）日：2002-12-31